drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic)
drug_description
Reference product (Erbitux); a recombinant chimeric anti-EGFR IgG1 monoclonal antibody that binds EGFR, blocks ligand binding and receptor activation, induces receptor internalization, inhibits downstream signaling (RAS–RAF–MEK–ERK, PI3K–AKT), and mediates ADCC.
nci_thesaurus_concept_id
C1723
nci_thesaurus_preferred_term
Cetuximab
nci_thesaurus_definition
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.
drug_mesh_term
Cetuximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Cetuximab is a chimeric IgG1 monoclonal antibody against EGFR (ErbB1/HER1). It binds the extracellular domain of EGFR, blocks ligand (EGF/TGF-alpha) binding, prevents receptor activation and dimerization, promotes receptor internalization, and inhibits downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling, reducing proliferation and survival of EGFR-expressing tumor cells; its IgG1 Fc can also mediate ADCC.
drug_name
cetuximab
nct_id_drug_ref
NCT06309043